Sanaria Inc.
Biotechnology company focused on development, manufacture and clinical evaluation of whole‑parasite sporozoite vaccines against Plasmodium falciparum. Activities include preclinical R&D, genetic attenuation of parasites, GMP production and cryopreservation of sporozoite reagents and challenge mosquitoes, assay development, controlled human malaria infection (CHMI) services, and coordination of an international sporozoite research consortium.
Industries
Nr. of Employees
medium (51-250)
Patents
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US-11760794-B2
View Details
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US-11760794-B2
View DetailsProducts
Aseptic purified cryopreserved sporozoite vials
Vialed, aseptic, purified and cryopreserved Plasmodium falciparum sporozoites for research and clinical applications.
Plasmodium reagent slides
Slides for immunofluorescence assays to detect antibodies against sporozoite and erythrocytic stages.
Anopheles reagents and derived mosquito materials
Aseptic and non‑aseptic Anopheles stephensi mosquitoes and derived materials for laboratory research.
Monoclonal antibodies for Plasmodium research
Monoclonal antibodies against Plasmodium antigens supplied for research use.
Infectious Sanaria® PfSPZ (150,000 PfSPZ)
Purified, vialed, cryopreserved, aseptic infectious PfSPZ for research use.
PfSPZ Challenge
Live, aseptic and non-aseptic P. falciparum-infected mosquitoes used for conducting controlled human malaria infections (CHMIs).
Aseptic purified cryopreserved sporozoite vials
Vialed, aseptic, purified and cryopreserved Plasmodium falciparum sporozoites for research and clinical applications.
Plasmodium reagent slides
Slides for immunofluorescence assays to detect antibodies against sporozoite and erythrocytic stages.
Anopheles reagents and derived mosquito materials
Aseptic and non‑aseptic Anopheles stephensi mosquitoes and derived materials for laboratory research.
Monoclonal antibodies for Plasmodium research
Monoclonal antibodies against Plasmodium antigens supplied for research use.
Infectious Sanaria® PfSPZ (150,000 PfSPZ)
Purified, vialed, cryopreserved, aseptic infectious PfSPZ for research use.
PfSPZ Challenge
Live, aseptic and non-aseptic P. falciparum-infected mosquitoes used for conducting controlled human malaria infections (CHMIs).
Services
Provision of vialed, aseptic, purified and cryopreserved sporozoites (attenuated and non‑attenuated) and other Plasmodium life stages for research and clinical use.
Production and provision of Plasmodium‑infected mosquitoes and derived material to support controlled human malaria infection studies.
Automated immunofluorescence, inhibition of sporozoite invasion and ELISA services for antibody detection and functional assessment in microtiter plate formats.
Custom manufacture of Plasmodium species reagents to customer specifications, including production scale‑up and GMP campaigns where required.
Provision of vialed, aseptic, purified and cryopreserved sporozoites (attenuated and non‑attenuated) and other Plasmodium life stages for research and clinical use.
Production and provision of Plasmodium‑infected mosquitoes and derived material to support controlled human malaria infection studies.
Automated immunofluorescence, inhibition of sporozoite invasion and ELISA services for antibody detection and functional assessment in microtiter plate formats.
Custom manufacture of Plasmodium species reagents to customer specifications, including production scale‑up and GMP campaigns where required.
Expertise Areas
- Whole‑parasite vaccine development
- Genetic attenuation and parasite engineering
- Controlled human malaria infection models
- GMP biologics manufacturing and cryopreservation
Key Technologies
- Whole‑sporozoite vaccine platforms
- In vitro sporozoite production
- Genetic gene‑deletion engineering
- Cryopreservation and vialing of live biologicals
News & Updates
Participation by invitation in a public exhibition to raise awareness and engage stakeholders on malaria eradication efforts.
Publication and press reporting on methods enabling in vitro production of infectious sporozoites without mosquitoes, supporting scale‑up for research and vaccines.
Randomized, double‑blind, placebo‑controlled Phase 1 and 2 trials reporting safety and efficacy of a whole‑sporozoite vaccine in healthy adults and women anticipating pregnancy in Mali.
News feature describing development of injectable sporozoite formulations to accelerate clinical testing and material sharing.
Recognition of the company's CEO for accomplishments as a physician, scientist and entrepreneur.
Interview with company leadership discussing clinical trial progress and research approaches.
Participation by invitation in a public exhibition to raise awareness and engage stakeholders on malaria eradication efforts.
Publication and press reporting on methods enabling in vitro production of infectious sporozoites without mosquitoes, supporting scale‑up for research and vaccines.
Randomized, double‑blind, placebo‑controlled Phase 1 and 2 trials reporting safety and efficacy of a whole‑sporozoite vaccine in healthy adults and women anticipating pregnancy in Mali.
News feature describing development of injectable sporozoite formulations to accelerate clinical testing and material sharing.
Recognition of the company's CEO for accomplishments as a physician, scientist and entrepreneur.
Interview with company leadership discussing clinical trial progress and research approaches.